Inactive Instrument

News Walmer Capital Corp Toronto S.E.

Equities

WALh

CA93266C1077

End-of-day quote Toronto S.E. Other stock markets
-	-

Feb. 02	Nurexone Biologic Initiating European Orphan Drug Designation Process Following U.S. Grant; Comes After Its Shares Fell Near 5% Today	MT
Jan. 17	NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nurexone Biologic Initiating European Orphan Drug Designation Process Following U.S. Grant; Comes After Its Shares Fell Near 5% Today	Feb. 02	MT
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant	Feb. 02	AQ
Top 4 Spinal Injury Stocks for 2024 Watchlist (NRX.V, NVRO, SYK, BSX)	Jan. 23	AQ
Top 4 Spinal Injury Stocks for 2024 (NRX.V, NVRO, SYK, BSX)	Jan. 22	AQ
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research	Jan. 17	MT
Nurexone Biologic Inc. and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market	Jan. 17	CI
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market	Jan. 17	AQ
NurExone Closes $2 Million Private Placement	Jan. 05	MT
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million	Jan. 05	AQ
NurExone Biologic Inc. announced that it has received CAD 1.985758 million in funding	Jan. 04	CI
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences	Nov. 29	MT
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration	Nov. 29	AQ
NurExone Biologic's Q3 Loss Widens; to Submit IND Application With FDA For ExoPTEN by Q4'24	Nov. 24	MT
NurExone Biologic Inc. Appoints Eran Ovadya as Secretary	Nov. 24	CI
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 24	AQ
NurExone Biologic Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 24	CI
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment	23-10-30	AQ
Nurexone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of Exopten Therapy for Acute Spinal Cord Injury Treatment	23-10-30	CI
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee	23-10-19	AQ
Nurexone Biologic Inc. Appoints Teodoro Forcht Dagi to Scientific Advisory Board and Advisory Committee	23-10-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Walmer Capital Corp Toronto S.E.

Equities

WALh

CA93266C1077

Summary

Filters